CROs offering Discovery Research with Antibody-Drug Conjugate (ADC)
Discovery Research combined with Antibody-Drug Conjugate (ADC) is a common shortlist filter for sponsors evaluating CRO partners. This explore page lists organizations that publicly map to both dimensions, so you can move from taxonomy browsing to a tighter candidate set without rebuilding filters from scratch.
Profiles here are fit-first: open each listing for scope, geography, regulatory posture, and provenance-backed facts. The directory does not rank these rows as a single "best" answer — use them to assemble a right-sized outreach list for your program stage and quality bar.
When you need adjacent criteria (indications, claim status, or cross-category search), continue to the main search experience and layer filters on top of this service × modality starting point.
Auto-generated by BioBM Editorial AI.
Matching companies
- Aliri Bioanalysis
Bioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise.
- Aragen Life Sciences
Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
- BioDuro-Sundia
BioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.
- Certara
Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
- ChemPartner
Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
- Crown Bioscience
Preclinical oncology CRO offering 2,500+ PDX models, organoid and cell line databases, and translational platforms with biomarker discovery and AI-driven systems biology for drug development.
- Frontage Laboratories
Global pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
- KCAS Bio
Leading bioanalytical CRO with 45+ years of experience, supporting 315+ approved drugs through bioanalysis, biomarker, immunogenicity, flow cytometry, and clinical kitting services across US, EU, and Australia facilities.
- Oncodesign Services
Contract research organization specializing in drug discovery and preclinical services for oncology, inflammation, and infectious diseases since 1995.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- PozeSCAF Inc.
Preclinical drug discovery CRO combining proprietary generative AI platform AxDrug with computational chemistry, synthetic chemistry, and in vitro biology to accelerate hit discovery and lead optimization for biotech and pharma clients.
- Reaction Biology
Global preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- WuXi AppTec
Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Related: Discovery Research service page · Antibody-Drug Conjugate (ADC) modality page
Markdown mirror: /explore/svc_discovery_research/mod_adc.md